Meet the Biotech Stock That Just Jumped 251% Higher

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can turn a novel new molecule into a prized asset worth billions overnight.Unexpectedly good results from a phase 3 trial with underserved essential tremor patients recently drove shares of Praxis Precision Medicines (NASDAQ: PRAX) through the roof. From Oct. 14, 2025, through Oct. 22, 2025, shares of the clinical-stage drugmaker soared 251%.A new drug for millions of tremor-ridden patients who lack treatment options could be worth billions in annual sales. That said, Praxis is a pre-commercial company, which could make it too risky for many investors. Here's what you want to know about this business before taking a chance on its stock.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool